The association between oxidative stress markers and thiol/disulfide homeostasis in Turkish women who are not diabetic, at risk for diabetes, or have type 2 diabetes

Authors

  • Shilpadas Author
  • Shazia Author
  • Mojahidul Islam Author

Keywords:

diabetes mellitus, prediabetes, and oxidative stress

Abstract

Context and Objectives: Diabetes is one of the disorders characterized by a breakdown of thiol/disulfide homeostasis
(TDH).
The purpose of this research was to look at those who have type 2 diabetes, those who are prediabetic, and those
who have just been diagnosed with blood sugar levels to see how TDH relates to oxidative stress markers.
Methods: Our research included 26 women who did not have diabetes, 24 women who were prediabetic, and 19
women who had type 2 diabetes. Tests for type 2 diabetes mellitus were requested by all of them at the Diabetes
Polyclinic at Zonguldak Bulent Ecevit University's Health Practice and Research Center, Endocrinology and
Metabolism Diseases. The patient's medical records were combed through for demographic and laboratory
information. In order to study oxidative stress parameters and dynamic total DH, ELISA kits were used.
Compared to non-diabetics, type 2 diabetics had considerably higher total oxidant status (TOS), total thiol, and
disulphide levels (24.24±14.93 vs 14.14±12.19, 646.47±75.51 versus 470.88±180.85, and 179.32±51.24 versus
91.85±40.29, respectively). There was a significant positive connection (P=0.000) between TOS and levels of native
thiol, total thiol, and disulphide in type 2 diabetics. A strong positive association was seen in prediabetics between
total antioxidant capacity and total thiol levels (P<0.05), as well as between arylesterase and both native and total
thiol levels (P<0.05). However, no such association was detected for total antioxidant capacity

Downloads

Published

26-05-2022

How to Cite

The association between oxidative stress markers and thiol/disulfide homeostasis in Turkish women who are not diabetic, at risk for diabetes, or have type 2 diabetes. (2022). International Journal of Pharmacetical Sciences Letters, 12(2), 49-47. https://ijpsl.org/index.php/ijpls/article/view/37